Two pivotal trials were conducted to provide clinical data to support the use of CABOMETYX®(cabozantinib) in advanced renal cell carcinoma (RCC).
The CABOSUN study
In the pivotal, phase II, CABOSUN study, the efficacy and safety of cabozantinib was compared with sunitinib in the first-line treatment of RCC.1, 7, 8
The METEOR study
In the pivotal, phase III, METEOR study, the efficacy and safety of cabozantinib following prior vascular endothelial growth factor (VEGF)-targeted therapy was compared with everolimus in treatment for RCC.1, 9–11